Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Jury Rules For Florida Hospital That Deported Brain-Damaged Immigrant Patient
"In a benchmark case dealing with the obligations of hospitals toward uninsured illegal immigrants, a jury in Stuart, Fla., decided Monday that Martin Memorial Medical Center did not act unreasonably when it chartered a plane and repatriated a severely brain-injured Guatemalan patient against the will of his guardian," The New York Times reports.

Experts Launch Think Tank For Mystery Disease
Ten leading scientists in Europe have formed a Think Tank for ME and will hold their first meeting on the 13th of June. They want to initiate an effective research effort to find the secret behind the mystery disease that cripples an increasing number of lives. Myalgic Encephalomyelitis, often referred to as Chronic Fatigue Syndrome (CFS), is a disease which affects at least one million individuals in the US, and an even greater number in Europe. Despite the large number of people affected, there is a lack of serious large-scale research initiatives focused on the disease. The number of patients is rapidly increasing but healthcare personnel lack knowledge about existing research and possible treatments.
News of the day
L.A. Times, NYT Opinion Pieces Discuss International Women's Health Issues
The Los Angeles Times and the New York Times recently published opinion pieces examining issues related to international women"s health. Summaries appear below.~ Michelle Goldberg, Los Angeles Times: The solution to addressing issues of over-population and under-population in various parts of the world is "giving women more control over their fertility and their lives," Goldberg, author of "The Means of Reproduction: Sex, Power and the Future of the World," writes in a Times opinion piece. Goldberg says that both problems are "symptoms of countries" failures to meet women"s needs." Citing United Nations data, Goldberg writes that the world"s population is growing at an "unsustainable" rate of 78 million people annually, and it will probably continue to increase by 70 million or 75 million annually through 2020. Almost all of that growth will occur in developing countries, she says. "The ethical and effective way to counter rapid population growth is to bolster women"s rights and improve their access to family planning," as well as access to education, Goldberg writes, adding that "study after study has found that girls who go to school marry later and have fewer, healthier children." Meanwhile, some developed countries -- including Japan, Russia, Italy and Spain -- are seeing a decline in birth rates, a fact that some social conservatives are using "to argue for restrictions on women"s rights." According to Goldberg, "Fertility is reaching dangerously low levels in countries where social attitudes and institutions haven"t caught up with women"s desire to combine work and family. When faced with men who are unwilling to share domestic burdens, inflexible workplaces and day-care shortages, many women respond by having fewer children." However, "when societies make it possible for women to combine having children with pursuing their other ambitions, fertility rates are fine," Goldberg says. She adds, "Give women freedom and support, and they will find reproductive equilibrium, so that when societies do shrink or grow, they do so in a manageable way" (Goldberg, Los Angeles Times, 5/17).~ Nicholas Kristof, New York Times: About 500,000 women "die annually from complications related to pregnancy or childbirth without attracting much interest because the victims are typically among the most voiceless people in the world: impoverished, rural, uneducated and female," Kristof writes in a Times opinion piece. He adds, "It"s no mystery how to save the lives of pregnant women; what"s lacking is the will and res." Kristof writes that Sierra Leone, which has the highest maternal mortality rate in the world, "is now making progress with the help of the United Nations Population Fund." Former President George W. Bush cut off U.S. funding for UNFPA, but President Obama has restored the funding. Kristof adds that a bill (H.R. 1410) that would "establish American leadership in this area ... has attracted pathetically little attention." He continues that if the lives of women in West Africa "were a priority, there would be many simple ways to keep them alive," such as providing them with bed nets to help protect against malaria or iron tablets to fight anemia at a cost of "just a few dollars" (Kristof, New York Times, 5/17).
Oncology

AdvanDx Receives FDA 510(k) Clearance For GBS PNA FISH(R) For Rapid Detection Of Group B Strep From Lim Broths

AdvanDx announced it received FDA 510(k) clearance for GBS PNA FISH(R) for detection of Streptococcus agalactiae, aka Group B Strep, from turbid Lim Broths inoculated with vaginal and rectal swabs obtained from pregnant women between 35 and 37 weeks gestation. The 90 minute molecular diagnostic test enables rapid and highly sensitive detection of Group B Strep from Lim Broths to help detect colonization in pregnant women. According to the US Centers for Disease Control and Prevention (CDC), Group B Strep is the most common cause of neonatal morbidity and mortality. Approximately 1 in 4 pregnant women are colonized with Group B Strep and can transmit the bacterium to the newborn during delivery. To prevent the transmission and subsequent infection, women are routinely screened for colonization between 35 and 37 weeks gestation, and if positive, receive antibiotics at the start of labor to eradicate the bacteria. Accurate detection of Group B Strep colonization is therefore crucial to prevent as many infections as possible.(2) During the routine laboratory testing process, vaginal and rectal swabs from pregnant women are inoculated into selective enrichment broth, e.g. Lim Broth, and incubate overnight to stimulate the growth of Group B Strep bacteria. A sample is subsequently taken for further culture workup and identification using conventional, phenotypic methods. This process can take anywhere from 3 to 4 days, and while Lim Broth is highly sensitive and selective for Group B Strep, the subsequent workup and phenotypic identification can be time consuming and may miss some true positive samples.(3) GBS PNA FISH combines the high sensitivity of Lim Broth with the speed, accuracy and ease-of-use of the PNA FISH molecular diagnostic platform to provide accurate Group B Strep detection fit for the routine laboratory workflow. In a recent clinical study, GBS PNA FISH was shown to detect up to 42% more Group B Strep positives than conventional culture methods. The authors of the study also found that the test produced results 2 to 3 days faster and concluded that "use of the PNA FISH assay for the detection of GBS from Lim broth culture showed an increased sensitivity, required decreased specimen handling, and had a shorter turnaround time than culture."(1) "GBS PNA FISH brings another exciting application to the PNA FISH platform and is another critical tool for improving infection prevention and patient management," said Thais T. Johansen, President and CEO of AdvanDx. "The test will enable labs to provide fast and sensitive detection of Group B Strep that in turn may help clinicians provide better preventative care for more pregnant women and their newborns," Johansen added. About PNA FISH(R) PNA FISH is an easy-to-use and highly sensitive and specific fluorescence in situ hybridization (FISH) assay that uses PNA (peptide nucleic acid) probes to target species specific ribosomal RNA (rRNA) in live bacteria and yeast. The unique properties of the non-charged, peptide backbone of PNA probes enable the use of FISH assays in exceedingly complex sample matrixes, such as blood and blood cultures, and this in turn facilitates the development of very simple, yet very accurate tests that don"t require the extensive sample preparation necessary for other nucleic acid technologies. PNA FISH tests enable microbiology labs to provide rapid and accurate pathogen identification in hours instead of days. Clinical studies show that the significantly faster results help clinicians provide more appropriate patient therapy that saves lives, reduces unnecessary antibiotic use, reduces patient length of stay and reduces overall hospital costs. About AdvanDx AdvanDx is the world"s leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx"s easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs. AdvanDx"s products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care. References: (1) J Clin Microbiol. 2008 Oct;46(10):3470-2. (2) http://www.cdc.gov/groupBstrep (3) Clin Infect Dis. 2004 Oct 15;39(8):1129-35. AdvanDx


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009